MicroRNA

ARTHEx Biotech to Participate in the 3rd Annual Needham Private Biotech Company Virtual 1x1 Forum

Retrieved on: 
Mercredi, octobre 11, 2023
DM1, MicroRNA, Neuromuscular disease, Pharmaceutical industry

VALENCIA, Spain, Oct. 11, 2023 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, announced today that it will participate in the 3rd Annual Needham Private Biotech Company Virtual 1x1 Forum, taking place October 17-18, 2023.

Key Points: 
  • VALENCIA, Spain, Oct. 11, 2023 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, announced today that it will participate in the 3rd Annual Needham Private Biotech Company Virtual 1x1 Forum, taking place October 17-18, 2023.
  • Company management will participate in virtual one-on-one meetings with potential investors during the conference.
  • ARTHEx's lead program, ATX-01, is advancing into clinical development for the treatment of myotonic dystrophy type 1 (DM1), a rare progressive neuromuscular disease.

EQS-News: Abivax highlights obefazimod ulcerative colitis program with new data to be presented at the UEG Week 2023

Retrieved on: 
Lundi, octobre 2, 2023
Maintenance, Therapy, United European Gastroenterology, UEG, MicroRNA, Ulcerative colitis, Ulcer, Euronext Paris, UC, Patient, Blood, CEST, Safety, Pharmaceutical industry, Abivax

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Oral presentation of Phase 2b, 96-week, open-label, maintenance efficacy and safety in obefazimod-treated patients with moderately to severely active ulcerative colitis (UC)
    Moderated poster presentation highlighting correlation of pharmacokinetic (PK) parameters with enhanced expression of a single microRNA, miR-124, in blood of obefazimod-treated UC patients
    PARIS, France, October 2, 2023 – 06:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announced that three scientific abstracts on its lead drug candidate, obefazimod, will be presented during the United European Gastroenterology (UEG) Week meeting, October 14-17, 2023, in Copenhagen, Denmark.
  • “We continue to be encouraged by the emerging clinical profile of obefazimod based on the 96-week efficacy and safety data from our Phase 2b open-label maintenance study,” said Sheldon Sloan, M.D., M. Bioethics, Chief Medical Officer of Abivax.
  • “With the presentation of this new data and the underlying novel mechanism of action, obefazimod has the potential to advance the treatment paradigm for people living with ulcerative colitis.”
    For more information on the Abivax clinical program and company updates, please visit Abivax’s UEG booth at C2-32 or see the conference program at the UEG website .

ARTHEx Biotech to Present at Chardan's 7th Annual Genetic Medicines Conference

Retrieved on: 
Jeudi, septembre 28, 2023
MicroRNA, Conference, Pharmaceutical industry

VALENCIA, Spain, Sept. 28, 2023 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, announced today that it will present at Chardan's 7th Annual Genetic Medicines Conference.

Key Points: 
  • VALENCIA, Spain, Sept. 28, 2023 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, announced today that it will present at Chardan's 7th Annual Genetic Medicines Conference.
  • Frédéric Legros, Chairman and CEO, will deliver a presentation on Tuesday, October 3, 2023 at 8:30am ET.
  • Dr. Legros will also participate in one-on-one meetings with potential investors during the conference.

Deep Genomics Introduces the Most Advanced AI Foundation Model for RNA Disease Mechanisms and Candidate Therapeutics

Retrieved on: 
Mercredi, septembre 27, 2023
Technology, Research, Genetics, Biotechnology, Health, Pharmaceutical, Data Management, Science, Artificial Intelligence, Molecular biology, Database, DNA, Genotype, Drug development, Therapy, Classification, SBO, Genomics, Deep learning, MicroRNA, Gene expression, RNA, RBP, Wilson's disease, Manuscript, Protein, Machine learning, Long QT syndrome, ATP7B, Engineering, Drug discovery, Biology, AI, Exon, Gene, Polyadenylation, Vaccine, New York University

Deep Genomics, a leading AI drug development company focused on decoding biology to program life-changing medicines, announced today the release of the manuscript, “An RNA foundation model enables discovery of disease mechanisms and candidate therapeutics” introducing the company’s AI foundation model, BigRNA.

Key Points: 
  • Deep Genomics, a leading AI drug development company focused on decoding biology to program life-changing medicines, announced today the release of the manuscript, “An RNA foundation model enables discovery of disease mechanisms and candidate therapeutics” introducing the company’s AI foundation model, BigRNA.
  • As outlined in the manuscript, BigRNA accurately predicts the tissue-specific regulatory mechanisms of RNA expression and the binding sites of proteins and microRNAs, plus the effects of variants and candidate therapeutics.
  • Deep Genomics has shown that our unique AI foundation model, BigRNA, can utilize DNA sequences to accurately discover the effects of non-coding, missense and synonymous variants on tissue-specific gene regulation, identify new mechanisms of RNA biology, and design RNA therapeutic candidates,” said Brendan Frey, Ph.D., F.R.S.C., founder and chief innovation officer at Deep Genomics.
  • We believe that BigRNA and deep learning systems like it have the potential to transform the field of RNA therapeutics.”
    “Kudos to Brendan and the team at Deep Genomics for their remarkable research on developing the first foundation model for RNA therapeutics.

Co-Diagnostics, Inc. to Participate in 6th ACTC Conference in Skiathos, Greece

Retrieved on: 
Vendredi, septembre 22, 2023
Learning, DNA, Circulating tumor DNA, Infection, Liquid biopsy, Research, MicroRNA, SALT, Chinese, Sale, Diagnosis, FDA, Pharmaceutical industry

This year's meeting will focus on the latest advances and clinical applications of liquid biopsy, with presentations on CTCs, circulating tumor DNA, circulating miRNAs and more.

Key Points: 
  • This year's meeting will focus on the latest advances and clinical applications of liquid biopsy, with presentations on CTCs, circulating tumor DNA, circulating miRNAs and more.
  • More information about the conference can be found here .
  • Parties interested in learning more about the Company's products or research into liquid biopsy are invited to visit Booth #9.
  • The Co-Dx PCR Home platform is subject to FDA review and is not available for sale.

NanoString to Host Virtual Spatial Genomics Summit September 19

Retrieved on: 
Jeudi, septembre 14, 2023
Research, Other Health, Pharmaceutical, Data Management, Oncology, Technology, Genetics, Health Technology, Clinical Trials, Science, Biotechnology, Health, Other Science, Inflammation, Product management, University College London, Drug development, IBD, DSP, Griffith University, SMI, MicroRNA, Gene expression, Biomarker, WTA, Proteomics, Information, IPA, Protein, Data analysis, MD, Data, NanoString Technologies, Biology, Inflammatory bowel disease, Ecosystem, Northwestern University, Gene, Medical imaging, Microscope, Medicine

NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, announced it will host its fifth annual Spatial Genomics Summit , September 19th.

Key Points: 
  • NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, announced it will host its fifth annual Spatial Genomics Summit , September 19th.
  • “The Spatial Genomics Summit is an educational forum for showcasing hot-off-the-press datasets and breakthrough applications,” said Joe Beechem, Chief Scientific Officer of NanoString.
  • Joseph Beechem, Ph.D. Chief Scientific Officer, NanoString: Spatial Biology Roadmap: Transforming the Information Content Obtained from a Single Tissue Section.
  • The NanoString logo, NanoString, NanoString Technologies, GeoMx, CosMx, AtoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc., in the United States and/or other countries.

Global Musculoskeletal Disorders Drugs Market to Surge, Projected to Reach $109.4 Billion by 2029 with 4.2% CAGR - ResearchAndMarkets.com

Retrieved on: 
Mercredi, septembre 13, 2023
Health, Pharmaceutical, Online, Osteoarthritis, Prevalence, Route of administration, Arena Pharmaceuticals, Arthritis, Kirin-Amgen Inc v Hoechst Marion Roussel Ltd, Analgesic, COVID-19, Distribution (marketing), Ageing, Microsoft, Bone, DSM-IV codes, MicroRNA, Life expectancy, Musculoskeletal disorder, Hospital, Arthropathy, Market, Administration, Back pain, Disease-modifying antirheumatic drug, Compound annual growth rate, UCB, Acquisition, AbbVie, Eli Lilly and Company, Pharmacy, Human musculoskeletal system, Growth, Johnson & Johnson, Immunology, Merck & Co., Novartis, Pharmaceutical industry, Agriculture, Pfizer

The global Musculoskeletal Disorders Drugs Market is set to witness significant expansion, projected to reach a substantial value of $109.4 billion by 2029, with a steady Compound Annual Growth Rate (CAGR) of 4.2% during the forecast period.

Key Points: 
  • The global Musculoskeletal Disorders Drugs Market is set to witness significant expansion, projected to reach a substantial value of $109.4 billion by 2029, with a steady Compound Annual Growth Rate (CAGR) of 4.2% during the forecast period.
  • The rise in life expectancy and aging population leads to a surge in musculoskeletal diseases, boosting the demand for treatments and subsequently propelling market expansion.
  • High Prevalence of Musculoskeletal Diseases: Over 150 diseases and conditions fall under the category of musculoskeletal disorders, affecting individuals globally.
  • The prevalence of these disorders, such as arthritis, osteoarthritis, and back pain, drives the demand for drugs and treatment options.

NanoString Expands Partnerships with Contract Research Organizations Making Spatial Molecular Imaging Tools Widely Available to Global BioPharma Researchers

Retrieved on: 
Jeudi, septembre 7, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Health Technology, Genetics, Partnership, DSP, SMI, GCP, MicroRNA, Gene expression, RNA, Proteomics, Protein, Patient, Contract research organization, NanoString Technologies, Biology, Ecosystem, Gene, ChromeOS, Fine chemical, Macrogen

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, announced today three new Contract Research Organization (CRO) CosMxTM Spatial Molecular Imager partnerships.

Key Points: 
  • NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, announced today three new Contract Research Organization (CRO) CosMxTM Spatial Molecular Imager partnerships.
  • Macrogen, Propath UK, and Sirona Dx offer global biopharma customers new access to CosMx™ SMI technology for translational drug development.
  • “NanoString is honored to partner with these leading CROs and accelerate access to spatial biology capabilities for biopharma companies around the world,” stated Brad Gray, President and CEO of NanoString.
  • The NanoString logo, NanoString, NanoString Technologies, GeoMx, CosMx and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc., in the United States and/or other countries.

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy

Retrieved on: 
Mardi, septembre 5, 2023
Seizure, Clinical trial, GRIK2, MicroRNA, Investigational New Drug, Patient, POC, FDA, Temporal lobe epilepsy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Safety, Pharmaceutical industry

and AMSTERDAM, Sept. 05, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AMT-260, the Company’s gene therapy candidate for refractory mesial temporal lobe epilepsy ( MTLE ).

Key Points: 
  • and AMSTERDAM, Sept. 05, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AMT-260, the Company’s gene therapy candidate for refractory mesial temporal lobe epilepsy ( MTLE ).
  • AMT-260 comprises an AAV9 vector that locally delivers two engineered miRNAs designed to degrade the GRIK2 gene and suppress the aberrant expression of glutamate receptor subtype GLUK2 that is believed to trigger seizures in patients with refractory MTLE.
  • The second part is expected to be a randomized, controlled trial to generate proof of concept (POC) data.
  • The clinical trial is expected to begin patient screening in the fourth quarter of 2023.

Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Lundi, septembre 4, 2023
Intellectual property, Business development, Fragment crystallizable region, Society, Mont-Saint-Guibert, Fortification, CD19, Intrinsic termination, CD95, International Teletraffic Congress, ICLE, Gene editing, American depositary receipt, Anti-CD19 immunotoxin, CIITA, Immunotherapy, SITC, Research, T cell, CAR, Congress, Society for Immunotherapy of Cancer, Euronext Paris, International Conference on Nuclear Disarmament, Oslo, 2008, NKG2D, Patient, Brussels Stock Exchange, Cytokine, Dumont, PD-1, Lancet, MicroRNA, Gene, Lymphocyte, Conference, Management, Vaccine, Rare-earth element, Medical device, Pharmaceutical industry, Euronext

First Half 2023 and recent corporate highlights:

Key Points: 
  • First Half 2023 and recent corporate highlights:
    Georges Rawadi was appointed Chief Executive Officer of the Company as from April 27, 2023.
  • Georges Rawadi is a seasoned executive with over 20 years of experience in pharma/biotech, as research director, business developer, CEO, and board member.
  • He also has insightful knowledge of both the company and the CAR-T space as he spent four years at Celyad Oncology (2014-2018) as Vice-President Business Development & Intellectual Property (“BD & IP”).
  • Key financial figures for the first half of 2023, compared with the first half of 2022 and full year 2022, are summarized below: